Detalhe da pesquisa
1.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother
; 73(4): 72, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430405
2.
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Breast Cancer Res Treat
; 204(1): 123-132, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019444
3.
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
Oncologist
; 28(7): 640-e559, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129455
4.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997907
5.
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 41(3): 493-502, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171722
6.
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Cancer
; 128(1): 65-74, 2022 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478166
7.
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Cancer
; 128(9): 1801-1811, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35195913
8.
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
Oncologist
; 27(3): 175-182, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274716
9.
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 22(9): 1290-1300, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34339623
10.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
11.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297397
12.
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 20(4): 518-530, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30857956
13.
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
Oncologist
; 24(12): e1409-e1416, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420467
14.
Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply.
N Engl J Med
; 384(6): 584-585, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33567202
15.
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
Cancer
; 124(9): 1982-1991, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29451696
16.
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Cancer
; 124(11): 2355-2364, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29645086
17.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(6): 654-e58, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438092
18.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028407
19.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
20.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 18(7): 874-886, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28602779